The story of GLP-1 drugs keeps getting bigger. First they transformed the treatment of diabetes. Then they upended the ...

Women taking GLP-1 drugs 30 percent less likely to develop breast cancer, researchers say - About 42,140 women are expected ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

While interventional cardiology wasn’t directly aligned with drug discovery, interacting with patients every week and seeing their journeys and problems was instructive. For instance, you see that ...

A robotic arm slowly approached a glass vial (vial) the size of a finger. It paused as if gauging the position, then firmly ...

Glucagon-like peptide agonists (GLP-1s, like Ozempic, Wegovy, and Mounjaro) have been hailed as breakthroughs. From statins to Viagra, occasionally a drug development breakthrough occurs that is ...

MIT engineers have devised a new way to deliver certain drugs in higher doses with less pain, by injecting them as a suspension of tiny crystals. Once under the skin, the crystals assemble into a drug ...

As more continues to be understood about the health benefits associated with GLP-1 drugs, a growing body of science is aiming to answer whether the popular weight-loss medication can help with one of ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine New antiviral drugs in development could offer the ...

The FDA’s Center for Drug Evaluation and Research has accepted the first letter of intent for an in silico drug development tool into the agency’s Innovative Science and Technology Approaches for New ...

New active ingredients such as antibodies are usually tested individually in laboratory animals. Researchers have now developed a technology that can be used to test around 25 antibodies ...

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.